# Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation

> **NCT02123108** · PHASE4 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 59 (actual)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** Basiliximab
- **DRUG:** Tacrolimus
- **DRUG:** Tacrolimus
- **DRUG:** Mycophenolic Acid

## Key facts

- **NCT ID:** NCT02123108
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2022-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02123108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02123108, "Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA (Enteric Coated Mycophenolic Acid) Following Liver Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02123108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*